Press Releases Atara Biotherapeutics, Inc.

Equities

ATRA

US0465131078

Delayed Nasdaq Other stock markets 03:52:30 2024-04-29 pm EDT			5-day change	1st Jan Change
0.72 ^USD	+4.35%		+3.58%	+40.87%

Apr. 01	Stifel Adjusts Atara Biotherapeutics Price Target to $2.30 From $4.80, Maintains Hold Rating	MT
Mar. 29	Eric Dobmeier Not to Stand for Re-Election as Member of Board of Directors of Atara Biotherapeutics, Inc	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Apr. 05	BU
Atara Biotherapeutics: Q4 Earnings Snapshot	Mar. 28	AQ
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress	Mar. 28	BU
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy	Feb. 29	BU
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference	Feb. 28	BU
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis	Feb. 14	BU
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology	Jan. 31	BU
Latest Buzz on The Street: Noteworthy Developments at DYAI, ELEV, ATRA, ESPR, KAVL	Jan. 17	AQ
Atara Biotherapeutics Announces $15 Million Registered Direct Offering	Jan. 08	BU
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 08	BU
Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 04	BU
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories	Dec. 20	BU
Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting	Dec. 11	BU
ATARA BIOTHERAPEUTICS, INC. REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)	Dec. 04	AQ
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Dec. 01	BU
ATARA BIOTHERAPEUTICS TO PRESENT POSITIVE NEW TAB-CEL CLINICAL DATA DURING ORAL SESSION AT ESMO IMMUNO-ONCOLOGY ANNUAL CONGRESS 2023	Nov. 30	AQ
Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023	Nov. 29	BU
Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference	Nov. 22	BU
Atara Biotherapeutics To Participate at the Stifel Healthcare Conference	Nov. 10	BU
Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis	Nov. 08	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Atara Biotherapeutics, Inc.

Equities

ATRA

US0465131078

Press Releases

Filters